Wellington Management Group LLP Acquires 70,789 Shares of Y-mAbs Therapeutics, Inc. $YMAB

Key Points

• Wellington Management Group LLP has increased its holdings in Y-mAbs Therapeutics by 53.1%, acquiring a total of 204,052 shares worth approximately $904,000 as of the latest SEC filing.
• Y-mAbs reported a narrower than expected loss in its latest earnings report, with an EPS of ($0.07), outperforming the consensus estimate of ($0.27) and achieving revenue of $19.52 million in the quarter.
• Multiple analysts have recently downgraded Y-mAbs Therapeutics' stock ratings and set a new price target of $8.60, reflecting a cautious outlook as the average target price is currently $9.62.

Wellington Management Group LLP grew its holdings in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 53.1% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 204,052 shares of the company's stock after buying an additional 70,789 shares during the quarter. Wellington Management Group LLP owned approximately 0.45% of Y-mAbs Therapeutics worth $904,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Brooklyn Investment Group raised its stake in Y-mAbs Therapeutics by 4,563.8% in the 1st quarter. Brooklyn Investment Group now owns 5,923 shares of the company's stock worth $26,000 after purchasing an additional 5,796 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Y-mAbs Therapeutics in the 1st quarter worth about $49,000. Corton Capital Inc. bought a new position in shares of Y-mAbs Therapeutics during the 1st quarter worth approximately $55,000. ProShare Advisors LLC acquired a new stake in shares of Y-mAbs Therapeutics during the 4th quarter worth approximately $99,000. Finally, Exchange Traded Concepts LLC increased its stake in shares of Y-mAbs Therapeutics by 107.9% in the 1st quarter. Exchange Traded Concepts LLC now owns 26,762 shares of the company's stock valued at $119,000 after acquiring an additional 13,890 shares in the last quarter. 70.85% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

YMAB has been the topic of several research analyst reports. Cantor Fitzgerald set a $8.60 target price on shares of Y-mAbs Therapeutics and gave the stock a "neutral" rating in a research note on Tuesday, August 5th. Morgan Stanley set a $8.60 target price on Y-mAbs Therapeutics in a research note on Tuesday, August 5th. Canaccord Genuity Group lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating and decreased their target price for the company from $26.00 to $8.60 in a research report on Tuesday, August 5th. Brookline Capital Management lowered Y-mAbs Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Tuesday, August 5th. Finally, Oppenheimer downgraded Y-mAbs Therapeutics from an "outperform" rating to a "market perform" rating in a report on Tuesday, August 5th. Eight research analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of "Reduce" and an average price target of $9.62.

Y-mAbs Therapeutics Stock Down 0.1%

YMAB traded down $0.01 during midday trading on Thursday, reaching $8.58. 168,476 shares of the company's stock were exchanged, compared to its average volume of 536,109. The business has a 50-day simple moving average of $6.26 and a two-hundred day simple moving average of $5.25. The firm has a market capitalization of $389.65 million, a price-to-earnings ratio of -17.15 and a beta of 0.54. Y-mAbs Therapeutics, Inc. has a one year low of $3.55 and a one year high of $16.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last posted its earnings results on Friday, August 8th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.27) by $0.20. The business had revenue of $19.52 million during the quarter, compared to the consensus estimate of $18.40 million. Y-mAbs Therapeutics had a negative return on equity of 24.60% and a negative net margin of 26.03%. As a group, research analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.